Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4105353 | 0.92 | MAPK14 (0.85) | MAPK14MAPK11 | |
| SCHEMBL4107633 | 0.92 | MAPK14 (0.85) | MAPK14MAPK11 | |
| SCHEMBL4107460 | 0.91 | MAPK14 (0.79) | MAPK14MAPK11 | |
| SCHEMBL4405233 | 0.89 | MAPK14 (0.85) | MAPK14MAPK11 | |
| SCHEMBL4412457 | 0.88 | MAPK14 (1.00) | MAPK14MAPK11 | |
| SCHEMBL4406674 | 0.88 | MAPK14 (1.00) | MAPK14MAPK11 | |
| SCHEMBL4117296 | 0.87 | MAPK14 (0.77) | MAPK14MAPK11 | |
| SCHEMBL4408487 | 0.86 | MAPK14 (0.90) | MAPK14MAPK11 | |
| SCHEMBL4415407 | 0.86 | MAPK14 (1.00) | MAPK14MAPK11 | |
| SCHEMBL4112546 | 0.85 | MAPK14 (0.74) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363910-B1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | claimed |
| US-6670357-B2 | Antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | claimed |
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | claimed |
| EP-1562949-B1 | METHODS FOR THE PREPARATION OF PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-7034151-B2 | 1,4-dihydro-4-oxo-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylates; novel approach to the formation of the bicyclic heterocyclic ring system | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060041124-A1 | Process for preparing pyrrolotriazine kinase inhibitors | CHEN BANG-CHI | 2006-02-23 | — | — | US | disclosed |
| US-6867300-B2 | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6670357-B2 | Antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | MAPK1, MAPK3, MAPK6 | MAPK14 29/4885MAPK11 38/4885 |
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K5, MAPK1, MAPKAPK5 | MAPK14 29/4885MAPK11 33/4885 |
| US-20060041124-A1 | Process for preparing pyrrolotriazine kinase inhibitors | MAP3K15, MAP4K2, MAP3K5 | MAPK14 288/4885MAPK11 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.